Keeps Biopharma Inc. Periodic Report
AI summary · Not investment advice
Keeps Pharma sold KRW 68.4 billion in Q3 but lost KRW 4.98 billion from its main business, turning from profit to loss versus a year earlier.}
Operating profit · 3 months
KRW -5.0 billion
Key facts
- Revenue (3 months)
- KRW 68.4 billion
- Net income (3 months)
- KRW -5.2 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 40.9 billion
- Revenue (year to date)
- KRW 202.8 billion
- Operating profit (prior-year 3 months)
- KRW 1.4 billion
- Operating profit (year to date)
- KRW -8.0 billion
- Net income (prior-year 3 months)
- KRW -446.0 million
- Net income (year to date)
- KRW -8.6 billion
Commentary
AI commentary · Not investment advice
What happened
Keeps Pharma reported its consolidated results for the third quarter of 2026. Sales for the latest 3 months were KRW 68.44 billion. That is 67.2% higher than the same 3 months a year earlier (KRW 40.93 billion). It is 8.6% lower than the previous quarter.
In the company's terms
Operating profit (money earned from the core business) for the 3 months was a loss of KRW 4.98 billion. A year earlier, the same period showed a profit of KRW 1.45 billion, so it turned into a loss. Net income (the final profit after taxes and other costs) was a loss of KRW 5.17 billion. A year earlier, the net loss was KRW 0.45 billion.
What changes for shareholders
For the year to date (January 1 to September 30), sales were KRW 202.76 billion. Operating profit was a loss of KRW 8.04 billion. Net income was a loss of KRW 8.60 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
K